99mTc-CNDG Injection in the Diagnosis of Malignant Tumors

Last updated: September 3, 2023
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Genitourinary Cancer

Treatment

99mTc-CNDG SPECT/CT

Clinical Study ID

NCT06030817
K1999
  • Ages 18-70
  • All Genders

Study Summary

Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively high diagnostic costs, which to some extent limits its widespread clinical application. In comparison to Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) devices are more abundant and offer lower diagnostic expenses. With the utilization of Cadmium Zinc Telluride (CZT) crystals in SPECT and advancements in image reconstruction techniques, the resolution and sensitivity of SPECT is continually improving. Therefore, the development of a simplified and cost-effective novel SPECT tumor imaging agent holds significant practical significance. This study involved the design and synthesis of a glucose-derived ligand with a linker containing seven methylene units and an isonitrile group (CN7DG). The CN7DG ligand was labeled with 99mTc to prepare a more lipophilic 99mTc-CN7DG complex, aiming to investigate a novel SPECT imaging agent for tumor imaging.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-70 years old
  • Patients diagnosed with malignant glioma, colorectal cancer, pancreatic cancer, lungcancer, breast cancer, or other malignant tumors through imaging techniques such asMRI, CT, and ultrasound, and who are scheduled for surgical resection or biopsy
  • Solid tumor sizes greater than 2cm
  • Voluntarily agree to participate and sign an informed consent form
  • Can provide complete surgical records, pathological results, control data, andclinical follow-up results

Exclusion

Exclusion Criteria:

  • Pre-treatment such as chemotherapy and targeted therapy has been administered
  • Pregnancy and breastfeeding
  • Claustrophobia
  • The condition is severe and difficult to cooperate with
  • Unable to obtain relevant control imaging data and clinical information

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: 99mTc-CNDG SPECT/CT
Phase:
Study Start date:
August 11, 2023
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Peking Union Medical College Hospital

    Beijing, Beijing 100730
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.